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Abstract 
 
Background: There are more than 30 different sexually transmissible agents while the most common one is 
Chlamydia trachomatis. In this prospective study, we decided to compare the prevalence of infection in 
symptomatic and asymptomatic females. 
 
Methods: Two hundred sixty urine samples of women in two groups (symptomatic and asymptomatic) were 
collected from patients attending Mehrad Hospital in Tehran, Iran and tested by polymerase chain reaction. 
 
Results: Thirty nine women in both groups were infected (14.99%), while 27/130 subjects were in symptomatic 
group (20.76%), compared with 12/130 person in asymptomatic group (9.23%). No statistically significant differ-
ence was found between two groups. Data analysis showed infection with C. trachomatis in symptomatic women 
to be significantly associated with history of sexually transmitted infections, white blood cells in urine and epithelial 
cells in urine. 
 
Conclusion: The present study recommends that targeted screening programs in high risk sexually active 
women (like as individuals who had a history of STIs) are needed as part of case-finding strategies and treat-
ment. 
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Introduction 
 
Sexually transmitted infections (STIs) are the second 
major cause of unpleasant diseases in young adult 
women worldwide.1 Genital infection of Chlamydia 
trachomatis (C. trachomatis) is one of the most 
common STIs and is considered as the most common 
treatable and preventable of them with adverse con-
sequences like infertility and preterm delivery. Most 
infections in females (60-80%) are asymptomatic, but 
the disease spectrum includes mucopurulent cervicitis 
(MPC), endometritis, salpingitis, the urethral syn-
drome, proctitis, post-abortal pelvic sepsis and peri-
hepatitis.2 Nowadays, detection of STIs has improved 
with development of nucleic acid based amplification 
methods such as polymerase chain reaction (PCR) with 
>95% sensitivity and specificity for detection of C. 
trachomatis in urine.3 The important aspect of these 
assays is their capacity to be used on non-invasive 
samples such as first void urine (FVU), which can be 
self collected and therefore facilitates larger investiga-
tions on prevalence in many populations.4 
It is important to control the spread of C. trachomatis 
infection, and prevention is the key of this process. 
Prevention should be based on identification of symp-
tomatic and asymptomatic people, especially those at 
increased risk for acquisition of new infections.5 
Many developed countries established a national 
standard plan for screening of C. trachomatis infec-
tions6 but in many hospitals and clinics of Iran, there 
is no program for the screening of people. 
 
 
 
 
*Correspondence: Morteza Haghighi Hasanabad, MSc, Molecular 
and Cellular Biology Research Center, School of Medicine, Sab-
zevar University of Medical Sciences, No: 2; Sabzevar, 
Imam Reza Ave., Sabzevar, Iran. Tel/Fax: +98-571-4445648, 
 e-mail: mhaghighi.v@gmail.com 
Received: November 20, 2011 Accepted: January 27, 2012 
Fatholahzadeh et al. 
 
WWW.ircmj.com Vol 14 May 2012 290
The aim of this study was to determine the preva-
lence of C. trachomatis infections in 2 groups of fe-
males (symptomatic and asymptomatic) and related 
risk factors in order to accelerate progress towards the 
strategies of WHO for prevention and control of STIs.7 
 
 
Materials and Methods  
 
Two hundred and sixty urine samples of females who 
were in sexually active age (15-50 years) attending  
Mehrad Hospital in Tehran, Iran, were collected from 
May 2009 to April 2010. Referrals were divided into 
two groups including symptomatic women (SW) with 
signs and symptoms referable to the urinary-genital 
tract and asymptomatic women (AW) attending hos-
pital for nongenitourinary complaints. 
Exclusion criteria included menstruation, pregnan-
cy, consumption antibiotics in 3 past weeks, uro-
genital anomalies, kidney disease, catheter usage, 
cognitive impairments and severe diseases that pre-
cluded study interview.8 All participants signed a 
consent form. The Research Ethics Board at Tehran 
University of Medical Sciences approved this study. 
Ten ml of FVU were collected at least two hours 
after last urination in a sterile tube and biochemical 
analysis was done using standard Dipstick test.9 Sam-
ples were maintained at 4˚C for one night in order to 
decrease inhibitors in urine and then transported to 
the research laboratory on ice. Samples were centri-
fuged in 4˚C (6000 g for 30 min) and pellets were 
washed with PBS (Phosphate buffer saline) twice and 
prepared for DNA extraction.10 
Extraction was performed using DNG-Plus kit 
(Cinnagen, Tehran, Iran) based on following proto-
col: 100 µl of sample was mixed with 600 µl DNG 
solution in 1.5 ml Eppendorf tube and centrifuged at 
7000 g for 5 min, then 400 µl isopropanol was added, 
centrifuged at 12000 g for 10 min. The pellets were 
precipitated with 1 ml of 70% ethanol and centrifuged 
at 12000 g for 5 min (precipitation was done twice). 
Poured off ethanol was allowed for air dry, finally 
DNAs were dissolved in 30 µl TE (Tris-EDTA) buff-
er and stored at -70˚C until use for PCR.11 
To establish condition for diagnostic procedure, 
we set up PCR using positive control DNA from C. 
trachomatis serovar L2 type strain 434/Bu (ATCC 
VR-902B). Amplification reactions were performed 
in a final volume of 20 µl containing 1 µl of positive 
DNA, 2 µl of the Master mix PCR solution (Bioatlas 
Mastermix, B.T. 10501) and 0.5 µl of each reverse 
and forward primer. 
The primers KL1 (5´-TCCGGAGCGAGTTACGA 
AGA-3´) and KL2 (5´-AATCAATGCCCGGGATT 
GGT-3´) were used to amplify a specific 241 bp 
fragment of the C. trachomatis cryptic plasmid 
gene.12 
The amplification was performed on a PCR sys-
tem (TECHNE, FTC 51H2D). The reaction involved 
one cycle at 94˚C for 5 min, followed by 30 cycles of 
denaturation at 94˚C for 40 sec, annealing at 58˚C for 
45 sec and extension at 72˚C for 40 sec, followed by 
one last elongation at 72˚C for 8 min. The PCR prod-
ucts were analyzed by electrophoresis in the 0.5% 
TBE buffer through 1% agarose gel, stained with eth-
idium bromide (1ng/ml), and DNA bands were visu-
alized using a UV transilluminator. 
Data were analyzed using SPSS for Windows 
(Version 15, Chicago, IL, USA). To examine possible 
associations between a positive test and risk factors, a 
multivariate analysis was performed. All associations 
with a p value < 0.05 were as significant. Moreover, 
for showing the strength of association between vari-
ables, common odds ratio (%95 CI.) was estimated. 
 
 
Results 
 
Of the 260 women recruited in this study, a high pro-
portion of them were older than 30 years old (69.2% 
of SW and 63.0% of AW). Moreover, 73.0% of par-
ticipants in each group were married and 45.3% of all 
had at least diploma or university educations (42.3% 
in SW and 48.4% in AW). Also in symptomatic 
group, dysuria and vaginal discharge were common 
symptoms consecutively. 
Genital infections of C. trachomatis were detected 
in 39 out of 260 women in total (14.99%). There were 
27/130 patients in symptomatic group (20.76%), 
compared with 12/130 patients in asymptomatic 
group (9.23%). No association was found between 
two groups. Data analysis showed infection with C. 
trachomatis in SW that was significantly associated 
with history of STIs, WBC in urine and epithelial 
cells in urine (p≤0.05). Figure 1 shows the 241 bp 
amplified fragment of cryptic plasmid gene. 
Table 1 illustrates statistical analysis results of im-
portant variables in women with positive C. tracho-
matis infection. In this table, history of STIs was seen 
in 29.2% of SW and 26.9% of AW in total. Also data 
analysis revealed that a high rate of white blood cells 
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in urine of SW (81/130) and 37.6% of AW, In addi-
tion, about epithelial cells in urine, data showed 
53.8% of SW and 43.0% of AW were in high range 
based on dipstick tests. 
Discussion 
 
There are few studies in Iran that report the preva-
lence of C. trachomatis from 14% to 24% in symp-
tomatic women,11 but some limitation of these studies 
should be mentioned for preventing bias. Firstly, the 
 
Fig. 1: lane1: Control positive of C. trachomatis, Lane2: 100bp ladder, Lane3: positive sample. 
 
 
Table 1: Important variables in women with positive chlamydial infection.
Cause Yes No P value Odd ratio
History of STIs  2.954 
SW 15 12 ≤0.05  
AW 4 8 NSa 
History of abortion  1.768 
SW 13 14 NS  
AW 3 9 NS 
History of PTD  1.455 
SW 7 20 NS  
AW 1 11 NS 
IUD Usage  1.510 
SW 14 13 NS  
AW 4 8 NS 
WBC in urineb  
SW 9  18  ≤ 0.05 
AW 4  8  NS 
Epithelial cells in urineb  
SW 7  20  ≤ 0.05 
AW 6  6  NS 
aNot Significant, bYes means High and No means few+ moderate in Dipstick test, symptomatic women (SW), 
asymptomatic women (AW). 
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representative distribution of variables may be affect-
ed due to the small sample sizes of studies in the tar-
get populations. Secondly, the selection bias in partic-
ipants who consecutively recruited from the selected 
clinics or venues that may limit the generalizability of 
the results. This likelihood was moderate by the cho-
sen recruitment of participants in our study.  
The reported prevalence of C. trachomatis infec-
tion is low in several Eastern Mediterranean countries 
such as the one report from United Arab Emirates 
with 2.6% prevalence rate.12 In addition, a hospital-
based study from Jordan among symptomatic patients 
reported 4.6% prevalence rate,13 and in another study 
that compared infertility women with control group, 
reported 3.9% and 0.7% respectively.14 
Based on several studies conducted in developed 
countries, the prevalence of C. trachomatis infection 
varied with age, and young adult patients were con-
sidered a high-risk group.15 In our study, high preva-
lence of C. trachomatis was seen in 30-50 years old 
women and odd ratio analysis revealed C. tracho-
matis infection in this group to be about 1.5 folds 
more than women under 30 years old (29/39 
[OR=1.502]), and two previous studies which conduct-
ed in Islamic Republic of Iran confirmed our results.16 
Also, we found it remarkable that the prevalence rate 
among married women were almost two folds more 
than single women [OR=1.850], which the reason of 
this fact may be the result of social and cultural aspects 
and religious attitudes in Iranian society about legal 
marriage. 
The significant association between C. tracho-
matis infection with history of STIs and WBC in 
urine which was seen in symptomatic women is simi-
lar to studies conducted in Iran and United States of 
America.17,18 Decreased susceptibility to C. tracho-
matis infection in elderly has been attributed to epi-
thelial changes in uterine surface,19 and comparison in 
different age levels surveillance may result in this 
difference. According to previous data, C. tracho-
matis alters a variety of host cell responses including 
proinflammatory cytokine and chemokine secretion, 
inhibition of apoptosis, inhibition of IFN-α and induc-
ible MHC class I and II expression.20 Also, C. tra-
chomatis infected cells may interfere with rapid and 
essential innate immune responses.21 Although it can 
be related to first void urine, which contains a high 
level of PUS cells, but in symptomatic women, it was 
significant and may be important. 
It is clear that partner announcement alone is not 
adequate for an optimal reduction in the C. tracho-
matis prevalence rate, and targeted screening pro-
grams in sexually active people are needed as part of 
case-finding strategy. In a new study, we evaluated 
the prevalence of C. trachomatis and Mycoplasma 
genitalium in pregnant women, which the results 
were 14.79% and 2.04% respectively, and it seems 
that more attention are needed in this group.22 The 
programs should focus on repeated testing for indi-
viduals who are in high risk groups like as pregnant 
women and women who have had a history of STIs 
during the preceding years. In addition, we found it 
reasonable to recommend that all sexually active fe-
males with any genitourinary symptoms to be offered 
convenience screening for C. trachomatis infection 
firstly and all of married women behind that. 
In order to optimize this strategy, sexual health 
services should become widely available, and the ser-
vices should publicize in a comfortable and appealing 
way in country. However, asymptomatic C. tracho-
matis infected people have a key role in distribution 
of infection and may remain shadowy and therefore 
keep on spreading the infection to partners. Interven-
tions of variable content may lead to favored changes 
in information, manner, awareness, self-efficacy, 
skills, and behaviors such as using appropriate proce-
dures for contraceptive ways, sexually infection caus-
es, and practice of protected sexual manners. Finally, 
further studies in order to determine the prevalence of 
infection and correlations between infecting people 
and other variables are needed in other cities of Iran. 
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